Diligence memo · auto-generated · as of July 2, 2026
Solaxa Inc.
Solaxa Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Solaxa Inc. operates in Pharmaceuticals, based in BETHESDA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Solaxa Inc. has raised $1.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $729K on 2021-02-11.
Most recent recorded round closed around 2024-08-29.
Valuation (modeled)modeled
Provath models Solaxa Inc. at approximately $1.3M (range $171K–$4.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.49× the median modeled value of Pre-Seed Pharmaceuticals companies in 2022–2024 (38 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 22 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 26% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Eleison Pharmaceuticals Inc, Telomir Pharmaceuticals, Inc., Drusolv Therapeutics, Inc., TF Tech Ventures, Inc., Thyron Pharmaceuticals, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.